Published in Lancet on January 02, 1982
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev (2012) 1.22
Antimicrobial prophylaxis in immunocompromised patients. Drugs (1987) 0.79
Selective decontamination in neutropenic patients. Epidemiol Infect (1992) 0.78
Childhood acute lymphoblastic leukaemia: a review. J R Soc Med (1982) 0.75
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet (1980) 4.21
The tight junction protein ZO-1 is homologous to the Drosophila discs-large tumor suppressor protein of septate junctions. Proc Natl Acad Sci U S A (1993) 3.48
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
Combined management of malignant teratoma of the testis. Lancet (1979) 3.12
Foetal thymic transplant in a case of Digeorge's syndrome. Lancet (1968) 2.85
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65
Recognition of leukaemia cells as foreign before and after autoimmunization. Br Med J (1971) 2.50
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet (1979) 2.48
Implantation of a foetal thymus, restoring immunological competence in a patient with thymic aplasia (Digeorge's syndrome). Lancet (1968) 2.40
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet (1983) 2.33
Five-year analysis of protective isolation. Lancet (1971) 2.31
The place of bone-marrow transplantation in acute myelogenous leukaemia. Lancet (1980) 2.03
Parenteral acyclovir therapy for herpesvirus infections in man. Lancet (1979) 1.99
Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification. Eur J Surg Oncol (2013) 1.99
Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child (1972) 1.93
The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol (1996) 1.89
The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer (1983) 1.84
Localization and differential expression of two isoforms of the tight junction protein ZO-1. Am J Physiol (1992) 1.72
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet (1977) 1.69
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer (1999) 1.66
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
The surrogate light chain in B-cell development. Immunol Today (1993) 1.64
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J (1973) 1.50
Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br J Cancer (1978) 1.48
Non-seminoma germ cell tumours (malignant teratoma) of the testis. Results of treatment and an analysis of prognostic factors. Br J Urol (1981) 1.46
Outcome of biphenotypic acute leukemia. Haematologica (1999) 1.46
Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia. Bone Marrow Transplant (1999) 1.45
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer (2009) 1.44
A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer (1977) 1.43
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer (1977) 1.43
Remission of Crohn's disease following allogeneic bone marrow transplant for acute leukaemia. Hosp Med (1998) 1.42
Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med (1986) 1.42
Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia. Br Med J (1977) 1.41
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet (1978) 1.40
Problems of infection after bone marrow transplantation. J Clin Pathol (1983) 1.40
The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms. J Urol (1997) 1.40
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol (1986) 1.40
L-asparaginase in treatment of acute leukaemia and lymphosarcoma. Br Med J (1970) 1.39
High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukaemia. Med Pediatr Oncol (1992) 1.39
Serial study of T lymphocytes in childhood leukemia during remission. Pediatr Hematol Oncol (1993) 1.39
Tumour lysis syndrome, case report and review of the literature. Ann Oncol (1996) 1.39
Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol (2012) 1.38
High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer (1982) 1.37
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol (2000) 1.36
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Recovery of human foetal liver cells after storage in liquid nitrogen. J Clin Pathol (1968) 1.34
Risk factors for acute graft-versus-host disease. Br J Haematol (1987) 1.33
The Caenorhabditis elegans sex determining gene fem-3 is regulated post-transcriptionally. EMBO J (1992) 1.33
Combination chemotherapy in advanced and recurrent Hodgkin's disease. Natl Cancer Inst Monogr (1973) 1.33
Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet (1983) 1.31
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer (1975) 1.31
Pneumocystis carinii pneumonitis: a serological study. J Clin Pathol (1979) 1.30
Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet (1994) 1.29
Thymic transplantation in a case of chronic mucocutaneous candidiasis. Lancet (1971) 1.26
Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men. Br Med J (1976) 1.26
Hsp90 inhibitors in the clinic. Handb Exp Pharmacol (2006) 1.21
Testicular tumours. Clin Endocrinol Metab (1975) 1.20
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer (1979) 1.19
Further observations on patients with a chromosomal abnormality associated with polycythaemia vera. Br J Haematol (1968) 1.18
Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J R Soc Med (1983) 1.17